ReP USP - Resultado da busca

Artigo de periodico
Association between cigarette smoking and subclinical markers of cardiovascular harm (2025)
Yao, Zhiqi; Tasdighi, Erfan; Dardari, Zeina A; Jha, Kunal K; Osuji, Ngozi; Rajan, Tanuja; Boakye, Ellen; Rodriguez, Carlos J.; Lotufo, Paulo Andrade ; Benseñor, Isabela Judith Martins
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: FATORES DE RISCO, TABAGISMO, BIOMARCADORES, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
YAO, Zhiqi et al. Association between cigarette smoking and subclinical markers of cardiovascular harm. Journal of the american college of cardiology, v. 85, n. 10, p. 1018-1034, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/84754. Acesso em: 03 nov. 2025.
APA
Yao, Z., Tasdighi, E., Dardari, Z. A., Jha, K. K., Osuji, N., Rajan, T., et al. (2025). Association between cigarette smoking and subclinical markers of cardiovascular harm. Journal of the american college of cardiology, 85( 10), 1018-1034. doi:10.1016/j.jacc.2024.12.032
NLM
Yao Z, Tasdighi E, Dardari ZA, Jha KK, Osuji N, Rajan T, Boakye E, Rodriguez CJ, Lotufo PA, Benseñor IJM. Association between cigarette smoking and subclinical markers of cardiovascular harm [Internet]. Journal of the american college of cardiology. 2025 ; 85( 10): 1018-1034.[citado 2025 nov. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84754
Vancouver
Yao Z, Tasdighi E, Dardari ZA, Jha KK, Osuji N, Rajan T, Boakye E, Rodriguez CJ, Lotufo PA, Benseñor IJM. Association between cigarette smoking and subclinical markers of cardiovascular harm [Internet]. Journal of the american college of cardiology. 2025 ; 85( 10): 1018-1034.[citado 2025 nov. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84754
Artigo de periodico
The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? (2022)
Bocchi, Edimar Alcides ; Lima, Ivna Girard Cunha Vieira
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: RESULTADO DE TRATAMENTO, INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCHI, Edimar Alcides e LIMA, Ivna Girard Cunha Vieira. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis?. Journal of the american college of cardiology, v. 80, n. 6, p. 595-597, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50443. Acesso em: 03 nov. 2025.
APA
Bocchi, E. A., & Lima, I. G. C. V. (2022). The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? Journal of the american college of cardiology, 80( 6), 595-597. doi:10.1016/j.jacc.2022.05.028
NLM
Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? [Internet]. Journal of the american college of cardiology. 2022 ; 80( 6): 595-597.[citado 2025 nov. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50443
Vancouver
Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? [Internet]. Journal of the american college of cardiology. 2022 ; 80( 6): 595-597.[citado 2025 nov. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50443
Artigo de periodico
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020)
Santos Filho, Raul Dias dos ; Stein, Evan A.; Hovingh, G. Kees; Blom, Dirk J; Soran, Handrean; Watts, Gerald F; Lopez, J. Antonio G; Bray, Sarah; Kurtz, Christopher E; Hamer, Andrew W
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: HIPERCOLESTEROLEMIA, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS, ANTIMETABÓLITOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 75, n. 6, p. 565-574, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.12.020. Acesso em: 03 nov. 2025.
APA
Santos Filho, R. D. dos, Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., et al. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, 75( 6), 565-574. doi:10.1016/j.jacc.2019.12.020
NLM
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Vancouver
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Artigo de periodico
Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study (2020)
Boccara, Franck; Kumar, Princy N; Caramelli, Bruno ; Calmy, Alexandra; Lopez, J. Antonio G; Bray, Sarah; Cyrille, Marcoli; Rosenson, Robert S
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: ESTATINAS, COLESTEROL, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS, DISLIPIDEMIAS, HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCARA, Franck et al. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study. Journal of the american college of cardiology, v. 75, n. 20, p. 2570-2584, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2020.03.025. Acesso em: 03 nov. 2025.
APA
Boccara, F., Kumar, P. N., Caramelli, B., Calmy, A., Lopez, J. A. G., Bray, S., et al. (2020). Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study. Journal of the american college of cardiology, 75( 20), 2570-2584. doi:10.1016/j.jacc.2020.03.025
NLM
Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study [Internet]. Journal of the american college of cardiology. 2020 ; 75( 20): 2570-2584.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2020.03.025
Vancouver
Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study [Internet]. Journal of the american college of cardiology. 2020 ; 75( 20): 2570-2584.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2020.03.025
Artigo de periodico
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome (2020)
Bittner, Vera A; Szarek, Michael; Aylward, Philip E; Bhatt, Deepak L; Diaz, Rafael; Edelberg, Jay M; Fras, Zlatko; Goodman, Shaun G; Halvorsen, Sigrun; Nicolau, José Carlos
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: SÍNDROME CORONARIANA AGUDA, LIPOPROTEÍNAS, ENZIMAS PROTEOLÍTICAS, LIPOPROTEÍNAS LDL, ESTATINAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BITTNER, Vera A et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the american college of cardiology, v. 75, n. 2, p. 133-144, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.10.057. Acesso em: 03 nov. 2025.
APA
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., et al. (2020). Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the american college of cardiology, 75( 2), 133-144. doi:10.1016/j.jacc.2019.10.057
NLM
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Nicolau JC. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [Internet]. Journal of the american college of cardiology. 2020 ; 75( 2): 133-144.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.10.057
Vancouver
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Nicolau JC. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [Internet]. Journal of the american college of cardiology. 2020 ; 75( 2): 133-144.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.10.057
Artigo de periodico
Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography (2020)
Furtado, Remo H. M; Nicolau, José Carlos ; Guo, Jianping; Im, Kyungah; White, Jennifer A; Sabatine, Marc S; Newby, L. Kristin; Giugliano, Robert P
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: SÍNDROME CORONARIANA AGUDA, MORFINA, ANGIOGRAFIA, DOENÇAS CARDIOVASCULARES, AGREGAÇÃO PLAQUETÁRIA, INTERAÇÃO DE MEDICAMENTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Journal of the american college of cardiology, v. 75, n. 3, p. 289-300, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.11.035. Acesso em: 03 nov. 2025.
APA
Furtado, R. H. M., Nicolau, J. C., Guo, J., Im, K., White, J. A., Sabatine, M. S., et al. (2020). Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Journal of the american college of cardiology, 75( 3), 289-300. doi:10.1016/j.jacc.2019.11.035
NLM
Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography [Internet]. Journal of the american college of cardiology. 2020 ; 75( 3): 289-300.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.11.035
Vancouver
Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography [Internet]. Journal of the american college of cardiology. 2020 ; 75( 3): 289-300.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.11.035
Artigo de periodico-carta/editorial
REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability (2018)
Avila, Monica Samuel; Bocchi, Edimar Alcides; Ferreira, Silvia Moreira Ayub
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: HIPERTENSÃO, EVENTO ADVERSO A MEDICAMENTO, TOXICOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AVILA, Monica Samuel e BOCCHI, Edimar Alcides e FERREIRA, Silvia Moreira Ayub. REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability. Journal of the american college of cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jacc.2018.07.003. Acesso em: 03 nov. 2025. , 2018
APA
Avila, M. S., Bocchi, E. A., & Ferreira, S. M. A. (2018). REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability. Journal of the american college of cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jacc.2018.07.003
NLM
Avila MS, Bocchi EA, Ferreira SMA. REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability [Internet]. Journal of the american college of cardiology. 2018 ; 72( 10): 1182-1183.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.003
Vancouver
Avila MS, Bocchi EA, Ferreira SMA. REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability [Internet]. Journal of the american college of cardiology. 2018 ; 72( 10): 1182-1183.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.003
Artigo de periodico
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
Everett, Brendan M.; Nicolau, Jose C.; DONATH, Marc Y.; PRADHAN, Aruna D.; THUREN, Tom; PAIS, Prem; GLYNN, Robert J; LIBBY, Peter; RIDKER, Paul M.
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 03 nov. 2025.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Artigo de periodico
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis (2018)
Tsimikas, Sotirios; Santos Filho, Raul Dias dos
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: ESTENOSE DA VALVA AÓRTICA, FATORES DE RISCO, DOENÇAS CARDIOVASCULARES, LIPOPROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TSIMIKAS, Sotirios e SANTOS FILHO, Raul Dias dos. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the american college of cardiology, v. 71, n. 2, p. 177-192, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2017.11.014. Acesso em: 03 nov. 2025.
APA
Tsimikas, S., & Santos Filho, R. D. dos. (2018). NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the american college of cardiology, 71( 2), 177-192. doi:10.1016/j.jacc.2017.11.014
NLM
Tsimikas S, Santos Filho RD dos. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis [Internet]. Journal of the american college of cardiology. 2018 ; 71( 2): 177-192.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2017.11.014
Vancouver
Tsimikas S, Santos Filho RD dos. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis [Internet]. Journal of the american college of cardiology. 2018 ; 71( 2): 177-192.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2017.11.014
Artigo de periodico
Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial (2018)
Corbalan, Ramon; Nicolau, Jose Carlos
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: ANTICOAGULANTES, FIBRILAÇÃO ATRIAL, ACIDENTE VASCULAR CEREBRAL, AMÉRICA LATINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CORBALAN, Ramon e NICOLAU, Jose Carlos. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, v. 72, n. 13, p. 1466-1475, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.07.037. Acesso em: 03 nov. 2025.
APA
Corbalan, R., & Nicolau, J. C. (2018). Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, 72( 13), 1466-1475. doi:10.1016/j.jacc.2018.07.037
NLM
Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
Vancouver
Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
Artigo de periodico
Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy (2018)
Senra, Tiago; Ianni, Barbara M; Costa, Ana C. P; Mady, Charles; Martinelli-Filho, Martino; Kalil-Filho, Roberto; Rochitte, Carlos E.
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: MIOCARDIOPATIA CHAGÁSICA, PROGNÓSTICO, MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SENRA, Tiago et al. Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy. Journal of the american college of cardiology, v. 72, n. 21, p. 2577-2587, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.08.2195. Acesso em: 03 nov. 2025.
APA
Senra, T., Ianni, B. M., Costa, A. C. P., Mady, C., Martinelli-Filho, M., Kalil-Filho, R., & Rochitte, C. E. (2018). Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy. Journal of the american college of cardiology, 72( 21), 2577-2587. doi:10.1016/j.jacc.2018.08.2195
NLM
Senra T, Ianni BM, Costa ACP, Mady C, Martinelli-Filho M, Kalil-Filho R, Rochitte CE. Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy [Internet]. Journal of the american college of cardiology. 2018 ; 72( 21): 2577-2587.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.08.2195
Vancouver
Senra T, Ianni BM, Costa ACP, Mady C, Martinelli-Filho M, Kalil-Filho R, Rochitte CE. Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy [Internet]. Journal of the american college of cardiology. 2018 ; 72( 21): 2577-2587.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.08.2195
Artigo de periodico
Clinical Genetic Testing for Familial Hypercholesterolemia (2018)
Sturm, Amy C.; Santos, Raul D.
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: HIPERCOLESTEROLEMIA, DOENÇAS CARDIOVASCULARES, COLESTEROL, CUSTOS DOS CUIDADOS DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STURM, Amy C. e SANTOS, Raul D. Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 72, n. 6, p. 662-680, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.05.044. Acesso em: 03 nov. 2025.
APA
Sturm, A. C., & Santos, R. D. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, 72( 6), 662-680. doi:10.1016/j.jacc.2018.05.044
NLM
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Vancouver
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Artigo de periodico
Pulmonary arterialhHypertension-related morbidity is prognostic for mortality (2018)
Mclaughlin, Vallerie V.; Souza, Rogerio
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: HIPERTENSÃO PULMONAR, MORBIDADE, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MCLAUGHLIN, Vallerie V. e SOUZA, Rogerio. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality. Journal of the american college of cardiology, v. 71, n. 7, p. 752-763, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2017.12.010. Acesso em: 03 nov. 2025.
APA
Mclaughlin, V. V., & Souza, R. (2018). Pulmonary arterialhHypertension-related morbidity is prognostic for mortality. Journal of the american college of cardiology, 71( 7), 752-763. doi:10.1016/j.jacc.2017.12.010
NLM
Mclaughlin VV, Souza R. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality [Internet]. Journal of the american college of cardiology. 2018 ; 71( 7): 752-763.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2017.12.010
Vancouver
Mclaughlin VV, Souza R. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality [Internet]. Journal of the american college of cardiology. 2018 ; 71( 7): 752-763.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2017.12.010
Artigo de periodico
SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial (2018)
Esper, Rodrigo B; Farkouh, Michael E; Ribeiro, Expedito E; Hueb, Whady Armindo; Domanski, Michael; Hamza, Taye H.; Siami, Flora S.; Godoy, Lucas Colombo; Mathew, Verghese; French, John; Fuster, Valentin
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: DIABETES MELLITUS, REVASCULARIZAÇÃO MIOCÁRDICA, CORONARIOPATIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ESPER, Rodrigo B et al. SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial. Journal of the american college of cardiology, v. 72, n. 23, p. 2826-2837, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.09.046. Acesso em: 03 nov. 2025.
APA
Esper, R. B., Farkouh, M. E., Ribeiro, E. E., Hueb, W. A., Domanski, M., Hamza, T. H., et al. (2018). SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial. Journal of the american college of cardiology, 72( 23), 2826-2837. doi:10.1016/j.jacc.2018.09.046
NLM
Esper RB, Farkouh ME, Ribeiro EE, Hueb WA, Domanski M, Hamza TH, Siami FS, Godoy LC, Mathew V, French J, Fuster V. SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 23): 2826-2837.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.09.046
Vancouver
Esper RB, Farkouh ME, Ribeiro EE, Hueb WA, Domanski M, Hamza TH, Siami FS, Godoy LC, Mathew V, French J, Fuster V. SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 23): 2826-2837.[citado 2025 nov. 03 ] Available from: https://doi.org/10.1016/j.jacc.2018.09.046

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Agência de fomento